The PROOF Centre is working closely with patients, clinicians, government, industry and health decision-makers to bring blood-based biomarker tests for heart, lung and kidney disease to the clinic sooner.

The Centre also contributes to benefits and opportunities to the research community. More than 65 Canadian researchers have already engaged the PROOF Centre team for:

  • advice on biomarker development, to be part of grant applications
  • assistance with strategic collaborations required in blood test development
  • linkages to commercial partners
  • general advice on strategies for utilization and commercialization.

Five research groups have formed collaborations with the PROOF Centre for use of our biomarker development process.

By working with the PROOF Centre, our pharmaceutical partners gain access to data for target identification and the use of blood tests to accelerate therapeutic development. At the same time, our diagnostic partners receive blood test content and access to early test adopters.

Within the next two years, the Centre will have posted data in an infrastructure available to Canadian researchers. Highly qualified people have been and will continue to be trained for the research community, for industry, and for healthcare organizations. To date, more than 20 trainees have specialized training in a scientific area along with biomarker business, development, analytic and clinical validity evaluation, and commercial arenas.